GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BeiGene Ltd
BeiGene is a biotech company building a bridge between the Chinese and Western oncology markets. Its shares reflect its global ambitions and success in developing and commercializing innovative cancer treatments worldwide.
Share prices of companies in the market segment - Cancer cure
Oncocyte is a company specializing in molecular cancer diagnostics. We classify it as part of the Cancer Cure sector, and the chart below shows the overall dynamics of this segment, which focuses on developing new treatments and diagnostics for oncological diseases.
Broad Market Index - GURU.Markets
Onconetix is a biopharmaceutical company focused on developing drugs for the treatment of oncology. It is a component of the GURU.Markets index. The chart below reflects the overall performance of the US market. See how this company's stock compares to the overall trend in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ONC - Daily change in the company's share price BeiGene Ltd
OncoC4 is a biopharmaceutical company developing immunotherapeutic drugs for the treatment of cancer. Its daily price change reflects the high volatility of the biotech sector. This indicator is important for analytical formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer cure
BeiGene, Ltd. is a global biotech company focused on oncology. This chart highlights the sector's high volatility. Comparing it to BGNE (Oncocyte, which used the ticker symbol ONC) helps us understand how its strong presence in the Chinese market impacts its risk profile.
Daily change in the price of a broad market stock, index - GURU.Markets
BeiGene is a global biotech company specializing in the development of innovative cancer treatments. Oncology is one of the most volatile biotech sectors, driven by clinical trial results. The chart below reflects these fluctuations, serving as a barometer for BeiGene's stock valuation.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BeiGene Ltd
BeiGene is a global biotechnology company, a leader in the development of innovative cancer treatments. Its shares reflect its success in drug research and commercialization worldwide, making a significant contribution to the dynamism of the healthcare sector.
Annual dynamics of market capitalization of the market segment - Cancer cure
BeiGene, Ltd. is a global biotechnology company focused on developing innovative cancer drugs. Its strategy includes both in-house research and partnerships to bring its products to the global market. This chart shows how its scientific potential and commercialization success compare to the broader biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
BeiGene is a biotech company focused on developing innovative cancer drugs. Its growth is entirely dependent on success in clinical trials and commercialization of its drugs in the global market, particularly in China and the United States. It's a science-driven growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BeiGene Ltd
BeiGene Ltd's (ONC) market capitalization based on Perf_Month_Co reflects its high sensitivity to the clinical success and commercialization of its oncology drugs. Monthly fluctuations in the chart are driven by trial phases, regulatory approvals (especially the FDA), and early sales of key targeted drugs.
Monthly dynamics of market capitalization of the market segment - Cancer cure
This chart reflects the dynamics of the entire pharmaceutical sector. For BeiGene, a global oncology company, it serves as a backdrop. Its outpacing growth relative to the sector reflects the success of its innovative drugs and its global expansion strategy, including the US market.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
BeiGene, Ltd. is a global biotechnology company focused on developing innovative oncology therapeutics. The company's future depends on the success of its clinical trials and expansion into new markets. The broader market chart serves as just a backdrop, showing how news about its drugs and partnerships has driven its stock price completely independently of the rest of the world.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BeiGene Ltd
Shares of BeiGene, a global biotech company specializing in oncology, reflect the hopes and risks in the fight against cancer on a weekly basis. Price movements reflect clinical trial results, drug approvals in the US and China, and partnerships with major pharmaceutical companies.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Oncology biotech is a sector where news about one company's clinical trials can impact the entire segment. Weekly industry performance reflects overall progress in the fight against cancer. The chart illustrates this highly volatile backdrop, which allows one to assess BeiGene's global reach.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
BeiGene is a global biotech company focused on developing oncology drugs. Its shares, like those of many biotech companies, can be highly volatile and react to research news. This chart will help you understand: is BeiGene living in its own world of clinical trials, or is the overall market environment influencing its stock price?
Market capitalization of the company, segment and market as a whole
ONC - Market capitalization of the company BeiGene Ltd
The BeiGene (ONC) market capitalization chart tells the story of one of China's leading biotech companies' rise to global prominence. Its dynamics reflect its success in developing innovative cancer treatments and their commercialization both in China and abroad. This growth reflects investors' bet on the company becoming a global player in oncology.
ONC - Share of the company's market capitalization BeiGene Ltd within the market segment - Cancer cure
BeiGene is a global biotech company specializing in the development of innovative cancer drugs. Its market share is rapidly growing thanks to the successful launch of its own drugs and partnerships. The chart demonstrates the importance of this rising star in oncology, which is building a bridge between China and the rest of the world.
Market capitalization of the market segment - Cancer cure
BeiGene is a global biotech company specializing in the development of innovative cancer drugs. The chart below shows the overall market capitalization of the oncology sector. Its rapid growth reflects the massive investment and scientific advances in this field, where BeiGene is one of the notable new players.
Market capitalization of all companies included in a broad market index - GURU.Markets
BeiGene is a global biotech company specializing in the development of innovative cancer drugs. Its high market cap reflects investors' hopes for a scientific breakthrough in one of the most complex areas of medicine. Its growth on the overall chart is a financial reflection of humanity's fight against cancer.
Book value capitalization of the company, segment and market as a whole
ONC - Book value capitalization of the company BeiGene Ltd
BeiGene, a biopharmaceutical company focused on oncology, has a balance sheet comprised of its cutting-edge research centers, patents for innovative drugs, and capital for global clinical trials. This provides a tangible, scientific foundation for the fight against cancer. How has this asset grown? The chart below shows the dynamics of its rapid growth.
ONC - Share of the company's book capitalization BeiGene Ltd within the market segment - Cancer cure
BeiGene is a biotech company focused on cancer treatment, which requires modern laboratories and manufacturing facilities. The chart shows the share of these science-intensive tangible assets in the pharmaceutical sector, reflecting the physical foundation of its fight against cancer.
Market segment balance sheet capitalization - Cancer cure
BeiGene's oncology drug development is a knowledge-intensive, but also capital-intensive business. Its ownership of large R&D centers and manufacturing facilities in China and the US makes it a heavyweight among many biotech startups.
Book value of all companies included in the broad market index - GURU.Markets
BeiGene's assets are not traditional factories, but cutting-edge research centers and manufacturing facilities in China and the United States, focused on developing innovative cancer drugs. Its book value reflects its scientific potential and growing global infrastructure. The chart shows the physical size of this rising star in global oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BeiGene Ltd
BeiGene, one of China's leading biotech companies, is valued by the market at multiples of its tangible assets. Investors are paying for its strong portfolio of oncology drugs, its global reach, and its potential to become a global leader in the fight against cancer.
Market to book capitalization ratio in a market segment - Cancer cure
BeiGene is a global biotech company specializing in the development of innovative cancer drugs. Its value lies in its scientific potential and pipeline. This chart shows the high premium investors are paying for its promising developments and growing global market presence.
Market to book capitalization ratio for the market as a whole
BeiGene is a global biotechnology company specializing in the development of innovative cancer drugs. Its value is based on the potential of its scientific developments and the commercial success of its existing drugs. This metric illustrates the high premium the market is willing to pay for breakthroughs in oncology, one of the largest and fastest-growing areas of medicine.
Debts of the company, segment and market as a whole
ONC - Company debts BeiGene Ltd
BeiGene, a global biotech company specializing in oncology, is in the process of rapidly growing and launching its drugs globally. The company is raising significant capital, including debt, to finance clinical trials and commercial infrastructure. This chart illustrates its R&D investment strategy and global expansion.
Market segment debts - Cancer cure
BeiGene is a global biotechnology company specializing in the development of innovative cancer treatments. Clinical trials and commercialization of oncology drugs require significant investment. This chart shows how the company uses raised capital, including debt, to finance its extensive development pipeline and global expansion.
Market debt in general
BeiGene is a global biotechnology company specializing in the development of innovative cancer treatments. The company is actively expanding its presence in global markets, requiring significant investments in research and commercialization. This chart helps understand how BeiGene finances its expensive operations compared to its competitors and the market as a whole.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BeiGene Ltd
BeiGene is a biotech company engaged in an expensive battle against cancer. Developing new drugs requires billions of dollars and years of research. This chart shows how BeiGene funds its research and development. It reflects the company's reliance on external capital, whether debt or equity, to support lengthy and risky clinical trials.
Market segment debt to market segment book capitalization - Cancer cure
BeiGene, a global biotech company specializing in the development of innovative cancer treatments, compares its debt to the overall market capitalization of the pharmaceutical sector. It shows how the company is funding its extensive clinical trials worldwide and building the commercial infrastructure to bring its products to market.
Debt to book value of all companies in the market
BeiGene, a global biotech company, invests heavily in research. This chart compares its debt to the overall market capitalization. It helps understand how the company finances its extensive R&D programs against the backdrop of general economic cycles, highlighting the long-term nature of its investments.
P/E of the company, segment and market as a whole
P/E - BeiGene Ltd
BeiGene is a global biotech company specializing in the development of innovative cancer treatments. This chart shows the high valuation investors place on its strong oncology pipeline and successful global expansion. The premium reflects high expectations for its scientific developments.
P/E of the market segment - Cancer cure
BeiGene is a global biotechnology company specializing in the development and commercialization of innovative cancer treatments. The company has a strong presence both in China and globally. This chart shows the average market value for the oncology sector, helping to understand how the market views BeiGene's scientific potential and pipeline.
P/E of the market as a whole
BeiGene is a global biotech company specializing in developing innovative cancer drugs. Is its valuation a reflection of the general investor appetite for risky biotech assets, as measured by this chart? Or is it a unique bet on the success of its drugs and its ability to compete with pharmaceutical giants in the global market?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BeiGene Ltd
BeiGene is a global biotechnology company specializing in the development of innovative cancer drugs. This chart reflects investors' high expectations for its pipeline and clinical trials. It assesses its potential to become a leader in global oncology and the commercial success of its products.
%20P%2FE%20BeiGene%20Ltd&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BeiGene-Ltd&v=1772636517863 "Chart of the company's future (projected) P/E BeiGene Ltd")
Future (projected) P/E of the market segment - Cancer cure
BeiGene is a global biotechnology company specializing in the development of innovative cancer treatments. This chart reflects analyst expectations for BeiGene's future profitability, which is heavily dependent on the success of its key drugs, such as Brukinsa, and its ability to compete with pharmaceutical giants in the global oncology market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772636517881 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
BeiGene is a global biotech company specializing in developing innovative cancer drugs. Their value is based on the potential of their research. This market sentiment chart shows how willing investors are to invest in long-term, risky oncology projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772636517888 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BeiGene Ltd
BeiGene is a global biotechnology company specializing in the development of innovative cancer drugs. This graph shows its path from research to commercialization. Revenue growth will depend on the success of its key drugs in global markets, including China and the US, and on the results of ongoing clinical trials.
Profit of companies in the market segment - Cancer cure
BeiGene is a global biotechnology company specializing in the development and commercialization of innovative cancer treatments. This chart shows its profitability in the oncology sector. The company has a strong presence both in China and globally, enabling it to conduct extensive research and develop new drugs.
Overall market profit
BeiGene is a global biotechnology company specializing in the development of innovative cancer drugs. Demand for its products is driven by medical needs, not economic cycles. However, the overall economic situation, reflected in this chart, influences the solvency of healthcare systems worldwide and the level of investment in research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BeiGene Ltd
BeiGene Ltd is a global biotechnology company specializing in the development of innovative cancer treatments. This chart reflects analysts' expectations for future earnings. The forecast depends on sales growth for already approved drugs, such as Brukinsa, and the success of clinical trials expanding their use.
%20profit%20of%20the%20company%20BeiGene%20Ltd&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BeiGene-Ltd&v=1772636517967 "Graph of future (projected) profit of the company BeiGene Ltd")
Future (predicted) profit of companies in the market segment - Cancer cure
BeiGene is a global biotechnology company specializing in the development of innovative cancer treatments. The oncology revenue projections shown in the graph demonstrate the enormous potential of these new treatments. This chart helps assess the competitiveness of BeiGene's drug portfolio in the global market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772636517998 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
BeiGene is a global biotechnology company specializing in the development of innovative cancer treatments. Demand for its products is driven by medical needs and is largely independent of the economy. However, the overall economic situation, as shown in the graph, affects the ability of healthcare systems to finance expensive treatments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772636518023 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BeiGene Ltd
BeiGene is a global biotech company specializing in the development of innovative cancer treatments. This chart shows the premium investors are paying for its rapidly growing drug sales revenue. A high premium reflects confidence in the company's scientific potential and its ability to compete in the global oncology market.
P/S market segment - Cancer cure
BeiGene is a global biotechnology company focused on developing and commercializing innovative cancer treatments. The company has a strong presence in both China and global markets. This chart shows the average market valuation for the sector, helping to understand how the market views the scientific potential and commercial prospects of BeiGene's oncology portfolio.
P/S of the market as a whole
BeiGene is a global biotech company specializing in the development of innovative cancer treatments. The company has a strong presence both in China and globally. This chart shows how the market values the fast-growing oncology company's revenue compared to the average valuations across all sectors.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BeiGene Ltd
BeiGene is a global biotechnology company focused on developing innovative cancer treatments. This chart shows investors' high expectations for its future revenue. This valuation is based on the success of its commercialized drugs and the strong potential of its extensive clinical pipeline.
%20P%2FS%20BeiGene%20Ltd&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BeiGene-Ltd&v=1772636518104 "The graph of the company's future (projected) P/S BeiGene Ltd")
Future (projected) P/S of the market segment - Cancer cure
BeiGene is a global biotechnology company focused on developing and commercializing innovative cancer treatments. This chart compares the company's estimated future sales with those of other cancer drugmakers. It reflects investor expectations for its flagship drugs and its ability to compete in the global oncology market.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772636518188 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
BeiGene is a global biotechnology company specializing in the development of innovative cancer treatments. Its success depends on the results of clinical trials and the launch of new drugs. This chart of overall market expectations for BeiGene is merely a backdrop, as its value is determined by scientific progress and the potential of its oncology portfolio.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772636518274 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BeiGene Ltd
This figure reflects the revenue of BeiGene, a global biotechnology company specializing in the development of innovative cancer treatments. Revenue is generated through sales of its proprietary oncology drugs worldwide, particularly in the US and China. Rapid revenue growth demonstrates the success of its research platform and the commercialization of breakthrough treatments.
Sales of companies in the market segment - Cancer cure
BeiGene is a global biotechnology company specializing in the development and commercialization of innovative cancer treatments. The company has a strong presence both in China and globally. This chart shows revenue in the cancer treatment sector. It reflects the global growth of the oncology market and the demand for new, more effective therapies that BeiGene is bringing to market.
Overall market sales
BeiGene Ltd. is a global biotechnology company specializing in the development of innovative cancer treatments. Demand for its drugs is driven by medical needs and is not dependent on short-term economic cycles. However, long-term economic growth, reflected in this chart, provides funding for healthcare systems, making advanced treatments more accessible.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BeiGene Ltd
BeiGene is a global biotechnology company specializing in the development of innovative cancer treatments. This revenue forecast chart reflects the commercial success of its oncology drugs. The rapid growth is driven by expectations for increased sales of its key drugs in the US, Europe, and China.
%20sales%20of%20the%20company%20BeiGene%20Ltd&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BeiGene-Ltd&v=1772636518487 "Schedule of future (projected) sales of the company BeiGene Ltd")
Future (projected) sales of companies in the market segment - Cancer cure
BeiGene is a global biotechnology company focused on developing innovative and affordable cancer treatments. The company has a strong presence in China and is actively expanding in the US and Europe. This chart shows projected revenue for the entire oncology drug sector, reflecting the enormous potential of this market and the expectations for new therapies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772636518517 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
BeiGene is a global biotechnology company specializing in the development of innovative cancer treatments. Demand for its products is driven by medical needs. However, successful sales and further research require stable funding for healthcare systems, which is ensured by the robust economic growth projected in this chart.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772636518544 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BeiGene Ltd
BeiGene is a global biotechnology company specializing in the development of innovative cancer treatments. This chart reflects its progress from research to commercialization. This growth is directly related to the increased sales of its oncology drugs in global markets, which underpins the company's path to sustainable profitability.
Market segment marginality - Cancer cure
BeiGene is a global biotech company specializing in the development of innovative cancer treatments. Its success depends on the profitability of approved drugs and progress in clinical trials. This chart shows the average profitability in the pharmaceutical industry. It helps assess the competitiveness of BeiGene's scientific platform and global strategy.
Market marginality as a whole
BeiGene is a global biotechnology company specializing in the development of innovative cancer treatments. Its success is determined not by the general economic cycles shown in this chart, but by scientific breakthroughs and successful clinical trials. Demand for anticancer drugs is inelastic, providing the company with growth potential regardless of economic conditions.
Employees in the company, segment and market as a whole
Number of employees in the company BeiGene Ltd
BeiGene is a global biotechnology company focused on developing innovative cancer treatments. Its rapid growth is driven by a strong pipeline and active clinical trials. This chart shows how the company is expanding its team of scientists and clinicians to fight cancer worldwide.
Share of the company's employees BeiGene Ltd within the market segment - Cancer cure
BeiGene is a global biotech company focused on cancer drug development. Its ambition to become a leader in oncology requires significant investment in global clinical trials and research. This metric tracks its rapid growth and growing influence, demonstrating its expanding share of specialized talent in the global oncology research sector.
Number of employees in the market segment - Cancer cure
BeiGene is a leading biotechnology company focused on developing innovative cancer treatments, with a strong presence both in China and globally. This chart demonstrates its rapid growth in oncology. The rapid expansion of its scientists, clinicians, and sales team reflects the successful launch of new drugs and an extensive clinical trial program.
Number of employees in the market as a whole
ON Semiconductor produces key chips for automotive and industrial electronics. Its global manufacturing footprint directly reflects two powerful trends: the electrification of transportation and industrial automation.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BeiGene Ltd (ONC)
BeiGene is a global biotech company focused on developing innovative cancer drugs. This timeline is very ambitious for them. The market evaluates not current sales, but the potential of their scientific developments. The success of a single blockbuster drug can justify the entire capitalization built by a relatively small team of scientists.
%20of%20the%20company%20BeiGene%20Ltd%20(ONC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BeiGene-Ltd-ONC&v=1772636518907 "Chart of market capitalization per employee (in thousands of dollars) of the company BeiGene Ltd (ONC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
BeiGene (ONC) is a biotech company specializing in cancer drug development, focusing on China and the United States. Like Regeneron, it is a pure R&D company. This metric, compared to the industry average, reflects how highly the market values their scientific potential and pipeline per scientist.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772636518917 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
BeiGene is a biotechnology company focused on developing innovative cancer treatments. This metric demonstrates how cutting-edge science creates enormous value. The efforts of its world-class scientific team are focused on creating breakthrough drugs, giving the company one of the highest market valuations per employee.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772636518921 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BeiGene Ltd (ONC)
BeiGene (ONC) is a Chinese biotech company focused on developing innovative cancer drugs. It is an R&D-focused business. This chart shows the company's success in commercializing its drugs globally. For a biotech company, high profit per employee is a sign of successful, high-margin drugs.
%20Chart%20BeiGene%20Ltd%20(ONC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BeiGene-Ltd-ONC&v=1772636518945 "Company Profit Per Employee (in thousands of dollars) Chart BeiGene Ltd (ONC)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
BeiGene is a Chinese biotech giant focused on oncology. This chart shows the benchmark for "Cancer Treatment." The average profit per employee in this sector (biotech) is astronomical (or negative if it's in the R&D stage). This is a "blockbuster business." A single successful drug patent can generate billions.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772636518981 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
BeiGene is a global biotech company specializing in the development of innovative cancer treatments. Its core business is cutting-edge science and clinical trials. This chart illustrates the enormous value per scientist that a company working at the forefront of the fight against cancer can generate.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772636519060 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BeiGene Ltd (ONC)
BeiGene is a global biotechnology company specializing in the development of innovative cancer drugs. This chart illustrates how the commercialization of successful drugs impacts financial performance. The increase in revenue per employee reflects successful sales and the company's global expansion.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BeiGene-Ltd-ONC&v=1772636519086 "Sales chart per company employee BeiGene Ltd (ONC)")
Sales per employee in the market segment - Cancer cure
BeiGene (ONC) is a biotech company with Chinese roots, focused on developing innovative cancer drugs. It's an R&D-intensive business, requiring significant investment in clinical trials. This chart shows the industry average per employee income, which helps assess the commercial viability of BeiGene's developments.
Sales per employee for the market as a whole
BeiGene is a global biotech company with Chinese roots, specializing in the development of innovative cancer drugs. Their core business is R&D and rapid drug delivery to the global market. This metric reflects the success of their team of scientists in creating and commercializing oncology blockbusters.
Short shares by company, segment and market as a whole
Shares shorted by company BeiGene Ltd (ONC)
BeiGene (ticker ONC on Nasdaq, not ONC) is a Chinese biotech company developing innovative cancer drugs. This chart shows bearish bets. Bears fear geopolitical tensions (US-China), risks in clinical trials, or fierce competition in the crowded oncology market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BeiGene-Ltd-ONC&v=1772636519231 "Short Shares Chart for the Company BeiGene Ltd (ONC)")
Shares shorted by market segment - Cancer cure
BeiGene (BGNE) is a global biotech company focused on developing innovative cancer drugs. They have a strong position in China and a growing presence in the US. This chart shows bets against the biotech. Shorts on BeiGene may be related to geopolitical risks (tensions between the US and China) or concerns about pricing pressure on their drugs in China, which could reduce their profitability.
Shares shorted by the overall market
BeiGene is a global biotech company specializing in the development of innovative cancer treatments. Like other biotech companies, it requires massive investments in R&D. This indicator of market fear is critical. When pessimism increases, investors flee unprofitable companies with a distant return on investment. For BeiGene, this means higher costs and increased difficulties in raising capital for its research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BeiGene Ltd (ONC)
BeiGene is a Chinese biotech company focused on oncology. The business faces a dual risk. When this *global* pessimism indicator rises, investors (1) flee emerging markets (like China) and (2) sell off unprofitable biotechs, fearing funding and regulatory risks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BeiGene-Ltd-ONC&v=1772636519353 "RSI 14 indicator chart for the company's stock BeiGene Ltd (ONC)")
RSI 14 Market Segment - Cancer cure
BeiGene (BGNE) is one of China's leading biotech companies, focused on developing innovative cancer treatments (like Brukins). This chart shows the overall sentiment in the biotech sector. It helps us understand: is BGNE overextended by the success of its drugs, or is the entire sector overbought?
RSI 14 for the overall market
BeiGene is a global biotech company specializing in the development of innovative cancer treatments. Biotech stocks are highly dependent on research results. This chart measures the overall market "temperature." It helps distinguish ONC movements driven by drug news from general market panic or euphoria in the healthcare sector.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ONC (BeiGene Ltd)
BeiGene is a global biotechnology company focused on developing and commercializing innovative cancer treatments. This chart shows the average Wall Street price target. It is based on analysts' forecasts for global sales of their blockbuster Brukins drug and clinical trial success.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ONC-BeiGene-Ltd&v=1772636519434 "A chart showing analyst consensus forecasts for the expected stock price. ONC (BeiGene Ltd)")
The difference between the consensus estimate and the actual stock price ONC (BeiGene Ltd)
BeiGene (BGNE) is a global biotech company with Chinese roots, focused on developing innovative cancer treatments. This chart is a barometer of hope for oncology. It shows the difference between the price and the consensus target, reflecting analysts' confidence in the commercial success of their blockbuster drug, Brukins, and other drugs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ONC-BeiGene-Ltd&v=1772636519553 "A chart showing the difference between the consensus forecast and the actual stock price. ONC (BeiGene Ltd)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
BeiGene (BGNE) is one of China's largest biotech companies, focused on developing innovative cancer drugs for the global market. This chart shows analysts' overall expectations for the biotech sector. It reflects whether experts believe the oncology R&D pipeline will be successful or whether they expect a decline.
Analysts' consensus forecast for the overall market share price
BeiGene Ltd. is a global biotech company specializing in the development of innovative cancer treatments. The company has strong positions in China and the United States. This chart shows overall market sentiment. For BeiGene, as a biotech company, overall risk appetite (reflected by analyst optimism) is critical to funding expensive research and development.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BeiGene Ltd
BeiGene is a global biotech company, originating in China but with a robust R&D presence in the US. They are focused on developing innovative cancer treatments. This chart is an assessment of their R&D platform. It reflects the success of their flagship drug, Brukins, in competing with major competitors and the market's confidence in their ability to create new oncology blockbusters.
AKIMA Market Segment Index - Cancer cure
BeiGene (BGNE) is a global biotech company with roots in China, focused on developing and commercializing innovative cancer treatments. This composite metric evaluates R&D. The chart shows the average value for the segment. This benchmark provides insight into how BeiGene's R&D pipeline and global strategy differentiate it from the average pharmaceutical company.
The AKIM Index for the overall market
BeiGene (BGNE) is a global biotech company founded in China, focused on developing innovative cancer treatments. Its blockbuster, Brukinsa, competes with global giants. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this biotech-inspired (but Chinese-rooted) science story stacks up against broader economic trends that influence risk appetite.
